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contrary, fetal human oxytocin at birth is of 
fetal origin, because its concentrations are 
higher in the umbilical artery than in the 
umbilical vein, and oxytocin is completely 
absent in cord blood of anencephalic new-
borns (Chard et al., 1971).
Parturition is a very complex process 
and oxytocin has its role particularly in 
contractility of myocytes (Smith, 2007). 
Exogenous oxytocin administration to 
pregnant woman strongly induces con-
tractions (Mori et al., 2011) but plasma 
oxytocin does not cross placenta toward 
the fetus (Chard et al., 1971; Patient et al., 
1999). However, by use of an in vitro system 
with dually perfused isolated cotyledons 
from term human placenta, bi-directional 
diffusion of oxytocin has been demon-
strated across the maternal-fetal barrier 
(Malek et al., 1996). Fetal oxytocin concen-
trations have been found to be either unaf-
fected by vaginal delivery, contractions, and 
by experimental hypoxic stress (Stegner 
et al., 1984; Thornton et al., 1993; Patient 
et al., 1999) or slightly increased (1.5- to 
2-fold) in umbilical cord blood after vagi-
nal delivery as compared to elective cesar-
ean section (Marchini et al., 1988; Lindow 
et al., 1998). Hence, fetal oxytocin release is 
not subject to birth stress and even if there 
is some crossing of the maternal-fetal bar-
rier, fetal oxytocin levels are barely altered. 
This is in sharp contrast to what has been 
observed for vasopressin. During vaginal 
delivery, there is an extremely steep rise of 
circulating vasopressin which is unparal-
leled by any changes that may occur during 
the life span of a human being (Chard et al., 
1971; Polin et al., 1977; Wellmann et al., 
2010; Benzing et al., 2011; Schlapbach et al., 
2011). The exceptional surge of circulat-
ing vasopressin (approximately 100-fold) is 
observed in infants born by vaginal deliv-
ery but not those born by elective cesarean 
section.
For many years, oxytocin has been viewed 
as the primary hormone edging endocri-
nology, behavior, and pain in mothers and 
infants around parturition. Very recent 
work puts the vasopressin receptor 1A in 
the focus of peripheral analgesia and pain 
relief in respect to circulating vasopressin 
and oxytocin. Here, we present a concise 
overview on these new findings, will discuss 
them in context of parturition, and will out-
line new avenues.
Both neuropeptides, oxytocin and vaso-
pressin, are synthesized in the hypothalamus 
from paraventricular and supraoptic nuclei 
and act either centrally within the brain or 
peripherally after release by the posterior pitu-
itary gland (Meyer-Lindenberg et al., 2011). 
In mammals, four receptors have been identi-
fied, the oxytocin receptor (OTR) and three 
receptors that respond primarily to vasopres-
sin, vasopressin receptor 1A (VR1A), VR1B, 
and VR2. Whereas VR1A and VR2 mediate 
the vasoactive and antidiuretic action, respec-
tively, in the periphery, central vasopressin 
functions are mediated by VR1A, VR1B, and 
OTR. Ligand binding of both centrally acting 
receptors, OTR and VR1A, activates the phos-
pholipase C beta signal transduction pathway 
(Jard et al., 1986; Arnaudeau et al., 1994; Ku 
et al., 1995; Phaneuf et al., 1995). Both the 
soluble ligands, oxytocin and vasopressin, as 
well as their receptors, OTR and VR1A, dis-
play high sequence homology, hence both 
ligands can activate both receptors (Chini 
and Manning, 2007).
In contrast to humans, the develop-
ment of paraventricular and supraop-
tic nuclei is late in rodents (Clancy et al., 
2001). Synthesis of vasopressin in rats starts 
between the 16th and 18th day of intrauter-
ine life and that of oxytocin few days after 
birth (Lipari et al., 2001). As the placenta 
of rodents is freely passable for both neu-
ropeptides, the newborn rodent oxytocin 
is mainly provided by the mother. On the 
A perpetually growing body of lit-
erature within the last four decades dem-
onstrate analgesic effects in human and 
rodents of both, oxytocin and vasopressin 
(Honda and Takano, 2009; Koshimizu and 
Tsujimoto, 2009; Schorscher-Petcu et al., 
2010). Oxytocin was reported to be anal-
gesic when administered into the brain (Ge 
et al., 2002; Gao and Yu, 2004), the spinal 
cord (Yu et al., 2003; Miranda-Cardenas 
et al., 2006; Condes-Lara et al., 2007), or 
systemically (Lundeberg et al., 1994; Reeta 
et al., 2006). Very recently, oxytocin was 
investigated in newborn Wistar rats in 
the tail-flick pain assay and the vocaliza-
tion assay of decerebrated newborn pups 
(Mazzuca et al., 2011). Whereas systemically 
(intraperitoneally) administered oxytocin 
was found to augment newborn rat anal-
gesia, while two OTR antagonists, atosiban 
and SSR126768A, delivered via the same 
route lowered analgesia (Mazzuca et al., 
2011). This is of interest as there is clini-
cal evidence of stress-induced analgesia in 
spontaneously delivered newborn infants 
(Bergqvist et al., 2009). It was concluded, 
that the same hormone (oxytocin) that 
triggers delivery also acts as a natural pain 
killer in the fetus at birth (Mazzuca et al., 
2011). Of note, the OTR antagonist atosiban 
employed in these experiments bind more 
readily to VR1A than to OTR (Akerlund 
et al., 1999) whereas SSR126768A is more 
OTR specific (Serradeil-Le Gal et al., 2004).
However, also very recently, elegant 
experiments with transgenic mice lacking 
the OTR or VR1A clearly demonstrated 
the indispensable prerequisite of VR1A 
for oxytocin-induced analgesia, at least 
at the peripheral level (Schorscher-Petcu 
et al., 2010). Systemically administered 
oxytocin was found to produce robust, 
dose-dependent analgesia in OTR KO 
mice but not in VR1A KO mice in a bat-
tery of thermal, mechanical, and chemical 
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In conclusion, we propose in human 
newborns a much stronger involvement of 
vasopressin and VR1A in mediating analge-
sia than noted so far based on the following 
reasons: First, no exchange of vasopressin or 
oxytocin across placenta was demonstrated 
in humans in vivo. Second, human fetuses 
independently produce both hormones and 
toward the end of gestation there is marked 
increase in the vasopressin/oxytocin ratio 
in the pituitary (Schubert et al., 1981). 
Third, normal vaginal delivery evokes a 
dramatic surge in vasopressin and if at 
all only a minor increase in fetal oxytocin 
concentrations. Fourth, the VR1A receptor 
appears to be central in vasopressin- and 
oxytocin-induced analgesia, but featured 
with much greater affinity for vasopressin 
than oxytocin.
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